Belimumab in the treatment of systemic lupus erythematosus: high disease activity predictors of response.

Annals of the Rheumatic Diseases
Ronald F van VollenhovenWilliam Freimuth

Abstract

To identify factors that predict response to belimumab treatment in the phase 3 BLISS trials of autoantibody-positive systemic lupus erythematosus (SLE) and further analyse clinical efficacy in various patient subsets. The BLISS trials compared belimumab 1 and 10 mg/kg versus placebo, all plus standard SLE therapy, over 52 or 76 weeks. Pooled subgroup analyses of week 52 SLE responder index rates (the primary endpoint in both trials) were performed based on demographic characteristics and baseline disease activity indicators. Pooled multivariate analysis was performed to determine predictors of response and treatment effect. Pooled univariate and multivariate analyses (N=1684) identified baseline factors associated with an increased benefit of belimumab versus placebo. These factors included the Safety Of Estrogens In Lupus Erythematosus National Assessment-Systemic Lupus Erythematosus Disease Activity Index (SELENA-SLEDAI) ≥10, low complement, anti-dsDNA positivity and corticosteroid use. Efficacy outcomes were assessed in the low complement/anti-dsDNA-positive and SELENA-SLEDAI ≥10 subgroups. Week 52 SLE Responder Index rates in the low complement/anti-dsDNA-positive subgroup were 31.7%, 41.5% (p=0.002) and 51.5% (p<0.001) wi...Continue Reading

References

Mar 7, 1968·The New England Journal of Medicine·P H Schur, J Sandson
Sep 10, 2005·Best Practice & Research. Clinical Rheumatology·Joan T Merrill, Jill P Buyon
May 17, 2007·Annals of the Rheumatic Diseases·G BertsiasUNKNOWN Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics
Feb 29, 2008·The New England Journal of Medicine·Anisur Rahman, David A Isenberg
Jun 10, 2009·Nature Reviews. Rheumatology·Chak Sing Lau, Anselm Mak
Aug 29, 2009·Arthritis and Rheumatism·Richard A FurieWilliam W Freimuth
May 3, 2013·The Journal of Rheumatology·Zahi ToumaDafna D Gladman

❮ Previous
Next ❯

Citations

May 23, 2013·Zeitschrift für Rheumatologie·R Fischer-BetzUNKNOWN Kommission Pharmakotherapie der DGRh
May 15, 2013·Current Rheumatology Reports·Daniel J Wallace
Mar 5, 2013·BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy·Philip R Harvey, Caroline Gordon
Apr 10, 2013·BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy·Moncef Zouali, Eugene A Uy
Nov 19, 2013·Best Practice & Research. Clinical Rheumatology·Ronald F van VollenhovenAdrian Levitsky
Nov 19, 2013·Best Practice & Research. Clinical Rheumatology·Anna Nuttall, David A Isenberg
Mar 5, 2013·Cellular & Molecular Immunology·Vera Sau-Fong ChanChak-Sing Lau
Oct 9, 2013·Nature Reviews. Rheumatology·Aikaterini Thanou, Joan T Merrill
Apr 19, 2013·The New England Journal of Medicine·Bevra Hannahs Hahn
Aug 7, 2013·Current Opinion in Rheumatology·Ronald F van Vollenhoven
May 7, 2013·BMC Medicine·Natasha JordanDavid P D'Cruz
Jun 17, 2014·La Presse médicale·Jacques-Eric GottenbergJean Sibilia
Apr 18, 2014·Annals of the Rheumatic Diseases·Ronald F van VollenhovenMatthias Schneider
Mar 13, 2014·Nature Reviews. Rheumatology·Fabien B VincentFabienne Mackay
Nov 6, 2013·Clinical and Experimental Rheumatology·Marta Mosca, Ronald van Vollenhoven
Apr 26, 2014·Seminars in Immunopathology·Iñaki Sanz
May 23, 2012·Current Rheumatology Reports·Katrina Shum, Anca Askanase
Jan 30, 2014·International Reviews of Immunology·Simonetta SalemiRaffaele D'Amelio
Jan 21, 2016·Expert Review of Clinical Immunology·David A Isenberg, Joan T Merrill
Mar 5, 2014·Expert Opinion on Emerging Drugs·Chi Chiu Mok
Mar 5, 2014·Expert Opinion on Biological Therapy·Chi Chiu Mok
Jun 25, 2013·Expert Opinion on Biological Therapy·Lukas Bossaller, Achim Rothe
Sep 4, 2015·Expert Opinion on Drug Metabolism & Toxicology·Natasha P Jordan, David P D'Cruz
Jan 24, 2013·Expert Opinion on Biological Therapy·Zahi ToumaDafna D Gladman
Jan 6, 2016·Nature Reviews. Rheumatology·C C Mok
Nov 20, 2015·Nature Reviews. Rheumatology·David S Pisetsky
Apr 30, 2013·Medicina clínica·Guillermo Ruiz-IrastorzaMunther Khamashta
Dec 26, 2012·Revista Clínica Espanõla·M Ramos-CasalsUNKNOWN Comité de Consenso sobre el uso de belimumab, Grupo de Trabajo de Enfermedades Autoinmunes Sistémicas (GEAS) de la Sociedad
Jul 28, 2012·La Presse médicale·Simon Bowman, Francesca Barone
Jun 19, 2012·The Medical Clinics of North America·Anne V Miller, Sriya K M Ranatunga
Dec 30, 2015·Clinical Rheumatology·Marie-Angélique De ScheerderAnne-Marie Bogaert
Feb 26, 2016·Expert Review of Clinical Pharmacology·Huza ZhangMaria J Cuadrado
Nov 14, 2015·Science China. Life Sciences·LiDan ZhaoXuan Zhang
Oct 2, 2015·Rheumatology·Jayoti Aytan, Marwan A S Bukhari
Apr 8, 2016·Expert Opinion on Biological Therapy·Morton A ScheinbergRenee S Martin
Apr 25, 2016·Best Practice & Research. Clinical Rheumatology·Jyoti BakshiAnisur Rahman
Feb 14, 2014·Expert Opinion on Therapeutic Targets·William Stohl
Jul 19, 2014·Rheumatic Diseases Clinics of North America·Anca D AskanaseCharles T Molta

❮ Previous
Next ❯

Methods Mentioned

BETA
BLISS

Clinical Trials Mentioned

NCT00424476
NCT00410384

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.